中軸型脊椎關節炎市場 - 全球產業規模、佔有率、趨勢、機會和預測，按類型、藥物類別、地區和競爭細分，2019-2029F

2023 年全球中軸型脊椎關節炎(axSpA) 市場估值為55.2 億美元，預計在預測期內將穩定成長，到2029 年複合年成長率為5.25%。一種主要影響脊椎的慢性發炎性疾病和薦髂關節，導致疼痛、僵硬和活動能力受損。隨著全球醫療保健格局的發展，axSpA 治療市場也不斷發展。近年來，在意識提高、診斷技術進步和患者人數不斷成長等因素的推動下，全球 axSpA 市場出現了顯著成長。該市場涵蓋一系列治療選擇，包括非類固醇抗發炎藥 (NSAID)、生物製劑和標靶治療。

市場概況
預測期	2025-2029
2023 年市場規模	55.2億美元
2029 年市場規模	75.2億美元
2024-2029 年複合年成長率	5.25%
成長最快的細分市場	非類固醇類抗發炎藥（NSAID）
最大的市場	北美洲

生物製劑徹底改變了 axSpA 的治療格局。阿達木單抗和蘇金單抗等藥物在控制症狀和減緩疾病進展方面顯示出顯著的功效。此外，旨在調節炎症相關特定途徑的標靶治療的出現正在擴大 axSpA 患者的治療手段。診斷技術也取得了重大進步，使得 axSpA 能夠更早、更準確地診斷。磁振造影 (MRI) 和其他影像方式在識別骶髂關節和脊椎發炎、促進及時介入和改善患者預後方面發揮著至關重要的作用。轉向更以患者為中心的方法是 axSpA 市場的一個顯著趨勢。患者權益團體和組織積極參與提高意識、促進研究和影響醫療保健政策，以更好地滿足 axSpA 患者的需求。對患者參與的重視預計將推動治療策略的進一步創新和改進。

主要市場促進因素

疾病意識的增強正在推動全球中軸型脊椎關節炎 (axSpA) 市場的發展

不斷增加的研發活動正在推動全球中軸型脊椎關節炎 (axSpA) 市場

主要市場挑戰

診斷不足及誤診

有限的治療選擇

治療費用高

漫長的法規核准流程

患者可近性和依從性

主要市場趨勢

技術進步

細分市場洞察

類型洞察

藥品類別見解

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：全球中軸型脊椎關節炎 (axSpA) 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型（僵直性脊椎炎 (AS) 和非放射學中軸型脊椎關節炎 (nr-axSpA)）
  • 依藥物類別（非類固醇類抗發炎藥 (NSAID)、糖皮質激素、抗風濕藥、其他）
  • 按地區
  • 按公司分類 (2023)
• 市場地圖
  • 按類型
  • 按藥物類別
  • 按地區

第 5 章：亞太地區中軸型脊椎關節炎 (axSpA) 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型
  • 按藥物類別
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第 6 章：歐洲中軸型脊椎關節炎 (axSpA) 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型
  • 按藥物類別
  • 按國家/地區
• 歐洲：國家分析
  • 法國
  • 德國
  • 西班牙
  • 義大利
  • 英國

第 7 章：北美中軸型脊椎關節炎 (axSpA) 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型
  • 按藥物類別
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第 8 章：南美洲中軸型脊椎關節炎 (axSpA) 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型
  • 按藥物類別
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 9 章：中東和非洲中軸型脊椎關節炎 (axSpA) 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按類型
  • 按藥物類別
  • 按國家/地區
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國

第 10 章：市場動態

• 促進要素
• 挑戰

第 11 章：市場趨勢與發展

• 最近的發展
• 產品發布
• 併購

第 12 章：全球中軸型脊椎關節炎 (axSpA) 市場：SWOT 分析

第 13 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第14章：競爭格局

• UCB SA
• Pfizer Inc.
• Abbott laboratories Inc.
• Johnson & Johnson
• Merck & Co., Inc.
• AbbVie Inc.
• Novartis AG
• Eli Lilly and Company
• Amgen Inc.
• GlaxoSmithKline plc
• NorthStar Rx LLC

第 15 章：策略建議

第16章調查會社について,免責事項

Global Axial Spondyloarthritis (axSpA) Market was valued at USD 5.52 Billion in 2023 and is anticipated to project steady growth in the forecast period with a CAGR of 5.25% through 2029. Axial Spondyloarthritis (axSpA) is a chronic inflammatory condition that primarily affects the spine and sacroiliac joints, causing pain, stiffness, and impaired mobility. As the global healthcare landscape evolves, so does the market for axSpA treatments. The global axSpA market has witnessed significant growth in recent years, driven by factors such as increased awareness, advancements in diagnostic techniques, and a growing patient population. The market encompasses a range of treatment options, including nonsteroidal anti-inflammatory drugs (NSAIDs), biologics, and targeted therapies.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 5.52 Billion
Market Size 2029	USD 7.52 Billion
CAGR 2024-2029	5.25%
Fastest Growing Segment	Non-steroidal anti-inflammatory drugs (NSAID)
Largest Market	North America

Biologics have revolutionized the treatment landscape for axSpA. Drugs such as adalimumab and secukinumab have shown remarkable efficacy in managing symptoms and slowing disease progression. Additionally, the emergence of targeted therapies, which aim to modulate specific pathways involved in inflammation, is expanding the therapeutic arsenal for axSpA patients. Diagnostic technologies have also witnessed significant advancements, enabling earlier and more accurate diagnosis of axSpA. Magnetic Resonance Imaging (MRI) and other imaging modalities play a crucial role in identifying inflammation in the sacroiliac joints and spine, facilitating timely intervention and improved patient outcomes. The shift towards a more patient-centric approach is a notable trend in the axSpA market. Patient advocacy groups and organizations are actively involved in raising awareness, promoting research, and influencing healthcare policies to better address the needs of axSpA patients. This emphasis on patient engagement is expected to drive further innovation and improvements in treatment strategies.

Key Market Drivers

Increasing Disease Awareness is Driving the Global Axial Spondyloarthritis (axSpA) Market

In recent years, there has been a significant upswing in global awareness surrounding Axial Spondyloarthritis (axSpA), a group of inflammatory rheumatic diseases that primarily affect the spine and sacroiliac joints. This heightened awareness has not only contributed to early diagnosis and treatment but has also driven the growth of the global axSpA market. As more people gain insights into this debilitating condition, the demand for innovative therapies and effective management strategies has surged, propelling the pharmaceutical and healthcare industries to new heights. One of the key factors fueling the growth of the axSpA market is the increased awareness leading to early detection and diagnosis. With the advent of educational campaigns, healthcare professionals and the general public alike are becoming more adept at recognizing the signs and symptoms of axSpA. This early identification is crucial for preventing long-term complications and improving the quality of life for individuals affected by the condition.

A notable driving force behind the growth of the axSpA market is the rise in patient advocacy groups and their efforts to raise awareness. These groups play a pivotal role in providing support, disseminating information, and advocating for improved treatment options. As patients become more empowered and informed, they actively seek out and demand advanced therapies, pushing pharmaceutical companies to invest in research and development for innovative solutions. The increasing awareness of axSpA has prompted significant investments in research and development, leading to technological advancements in both diagnostic tools and treatment modalities. Advanced imaging techniques, biomarker identification, and personalized medicine approaches are now at the forefront of axSpA management. This influx of cutting-edge technologies not only enhances the accuracy of diagnosis but also opens up new avenues for targeted and effective treatments.

Rising Research and Development Activities is Driving the Global Axial Spondyloarthritis (axSpA) Market

In the dynamic landscape of healthcare, the Global Axial Spondyloarthritis (axSpA) Market is undergoing a transformative phase, with research and development activities emerging as the driving force. Axial spondyloarthritis encompasses a group of inflammatory diseases primarily affecting the spine and pelvis, with ankylosing spondylitis being the most common form. As the world becomes increasingly attuned to the nuances of healthcare, the rising tide of awareness and research initiatives is reshaping the axSpA market. Research and development activities are at the forefront of the global battle against axSpA. The quest for more effective treatments, early diagnosis methods, and a deeper understanding of the disease's underlying mechanisms has sparked a surge in R&D initiatives. Pharmaceutical companies, academic institutions, and healthcare organizations are collaborating to bring innovative solutions to the forefront.

One of the notable trends in axSpA research is the emphasis on biologic therapies. These advanced treatments target specific pathways involved in the inflammatory process, offering patients a more targeted and personalized approach to managing their condition. The development of novel biologics is a testament to the commitment of researchers to enhance the quality of life for individuals living with axSpA. The adage "prevention is better than cure" holds true for axSpA, and researchers are investing efforts in developing methods for early diagnosis. Advances in imaging technologies and biomarker research are paving the way for more accurate and timely detection of axSpA, allowing for early intervention and better outcomes. The rising awareness of axSpA is not limited to the scientific community alone. Patients and advocacy groups are actively participating in raising awareness and influencing research agendas. This patient-centric approach ensures that the unique challenges faced by individuals with axSpA are considered in the development of new therapies and support services.

As research progresses, the global axSpA market is witnessing significant growth. The demand for innovative treatments and the increasing prevalence of axSpA worldwide are propelling market expansion. Pharmaceutical companies are investing in research ventures to gain a competitive edge and contribute to the global effort in managing this debilitating condition. Despite the promising developments, challenges persist. Regulatory hurdles, funding limitations, and the complexity of axSpA pose obstacles to researchers. However, these challenges also present opportunities for collaboration and innovation, fostering a resilient research ecosystem.

Key Market Challenges

Underdiagnosis and Misdiagnosis

One of the primary challenges in the axSpA market is the underdiagnosis and misdiagnosis of the condition. Axial spondyloarthritis is notoriously difficult to diagnose early on, leading to delays in treatment initiation. This delay not only impacts the patient's quality of life but also poses challenges for pharmaceutical companies seeking to develop targeted therapies. Efforts are being made to raise awareness among healthcare professionals and the general public about the signs and symptoms of axSpA. Educational campaigns and continuing medical education programs are crucial in improving early detection rates.

Limited Treatment Options

While there have been notable advancements in the treatment of axSpA, including the introduction of biologic therapies, the market still faces challenges related to limited treatment options. Some patients may not respond well to existing treatments, emphasizing the need for a diversified therapeutic approach. Pharmaceutical companies are investing heavily in research and development to explore new treatment modalities and therapeutic targets. This includes investigating the potential of precision medicine and personalized treatment plans to address the heterogeneity of axSpA.

High Treatment Costs

The cost of axSpA treatment, particularly biologics, can be prohibitively high. This poses a challenge for both patients and healthcare systems, limiting access to these advanced therapies. The economic burden may result in non-adherence to treatment plans, compromising long-term outcomes. Pharmaceutical companies are actively working on strategies to make treatments more affordable, including the development of biosimilars and exploring partnerships with healthcare payers to establish cost-effective reimbursement models.

Long Regulatory Approval Processes

The development and approval of new therapies for axSpA involve navigating complex regulatory processes, leading to lengthy timelines. This delay in bringing innovative treatments to market can impede progress in addressing the unmet needs of patients. Collaboration between pharmaceutical companies, regulatory bodies, and patient advocacy groups is essential to streamline regulatory processes. Expedited pathways for the approval of promising therapies can significantly impact the landscape of axSpA treatment.

Patient Access and Adherence

Ensuring patient access to axSpA treatments and promoting adherence to prescribed regimens remain significant challenges. Geographic disparities, limited healthcare infrastructure, and patient education gaps contribute to these challenges.

Patient support programs, telemedicine initiatives, and community outreach efforts are being implemented to enhance access and adherence. These initiatives aim to empower patients with information and support, fostering a more proactive approach to managing axSpA.

Key Market Trends

Technological Advancements

Advancements in diagnostic technologies have been instrumental in the early and accurate identification of axSpA, paving the way for improved patient outcomes. Modern imaging techniques, such as magnetic resonance imaging (MRI) and computed tomography (CT) scans, enable healthcare professionals to visualize inflammation and structural damage to the spine and sacroiliac joints with unprecedented detail. These tools facilitate quicker and more precise diagnoses, allowing for timely intervention and better disease management. The realm of axSpA treatment has been revolutionized by the advent of biological therapies and precision medicine. Biologics, which are genetically engineered proteins derived from living cells, target specific components of the immune system responsible for inflammation. This targeted approach not only enhances the efficacy of treatment but also minimizes side effects. Additionally, precision medicine tailors treatment plans based on an individual's genetic makeup, optimizing therapy outcomes and reducing the likelihood of adverse reactions.

The integration of digital health solutions is further propelling the axSpA market forward. Mobile applications, wearable devices, and remote monitoring technologies empower patients to actively participate in their healthcare journey. These tools provide real-time data on symptoms, physical activity, and medication adherence, enabling healthcare providers to personalize treatment plans and make informed decisions. Moreover, telemedicine has become increasingly prevalent, offering convenient access to specialized care and fostering continuous patient engagement. The continuous influx of investments into research and development is a driving force behind the technological strides in axSpA management. Pharmaceutical companies and research institutions are collaborating to explore novel therapeutic targets and develop innovative treatment modalities. From small molecule inhibitors to gene therapies, the pipeline of potential interventions is expanding, promising a future where axSpA can be managed more effectively and with fewer limitations on patients' quality of life. The interconnected nature of the global healthcare landscape has facilitated collaborative efforts in axSpA research and development. International conferences, research partnerships, and knowledge-sharing initiatives have accelerated the pace of innovation. The synergy of expertise from diverse regions has proven invaluable in understanding the complexities of axSpA and devising comprehensive solutions that cater to the varied needs of affected populations.

Segmental Insights

Type Insights

Based on the category of type, Ankylosing spondylitis (AS) emerged as the dominant player in the global market for Axial Spondyloarthritis (axSpA) in 2023. Ankylosing Spondylitis, a chronic inflammatory condition, primarily targets the spine, causing pain, stiffness, and impaired mobility. However, the focus on AS within the broader axSpA category has led to remarkable strides in research, diagnosis, and therapeutic interventions. Advancements in diagnostic technologies, including imaging techniques like magnetic resonance imaging (MRI), have enabled earlier and more accurate detection of AS. Timely diagnosis is crucial for initiating effective treatment and preventing long-term complications. The advent of biologic therapies has revolutionized the management of AS. These medications, such as tumor necrosis factor (TNF) inhibitors, target specific inflammatory pathways, providing relief to patients and slowing the progression of the disease. The success of biologics in AS has propelled research into other potential targets, expanding the arsenal of treatment options. The AS-dominated focus has paved the way for more patient-centric approaches in research and treatment. Understanding the unique needs and challenges faced by individuals with AS has led to tailored interventions and improved overall outcomes.

Drug Class Insights

The Non-steroidal anti-inflammatory drugs (NSAID) segment is projected to experience rapid growth during the forecast period. NSAIDs are a class of medications renowned for their anti-inflammatory, analgesic, and antipyretic properties. In the context of axSpA, these drugs play a pivotal role in managing symptoms and improving the overall quality of life for patients. Unlike disease-modifying antirheumatic drugs (DMARDs) and biologics, NSAIDs primarily target symptom relief, making them a first-line treatment option for many individuals diagnosed with axSpA. NSAIDs are effective in alleviating pain and reducing inflammation, providing much-needed relief for axSpA patients. Their ability to manage symptoms quickly makes them an attractive choice for both patients and healthcare providers. Early diagnosis and intervention are crucial in managing axSpA effectively. NSAIDs, due to their rapid onset of action, allow for early treatment, preventing the progression of the disease and improving long-term outcomes.

Compared to more advanced treatments like biologics, NSAIDs are generally more cost-effective. This affordability factor makes them accessible to a broader patient population, especially in regions where healthcare resources may be limited. Many axSpA patients prefer NSAIDs for their simplicity and ease of use. Oral administration and the absence of invasive procedures make NSAIDs a convenient choice for individuals seeking a less complicated treatment regimen. NSAIDs are often used in combination with other treatment modalities, such as physical therapy and lifestyle modifications, providing a comprehensive approach to axSpA management.

Regional Insights

North America emerged as the dominant player in the global Axial Spondyloarthritis (axSpA) market in 2023, holding the largest market share in terms of value. One of the key factors propelling North America to the forefront of the axSpA market is its commitment to cutting-edge research and development. The region boasts a network of renowned research institutions, pharmaceutical companies, and healthcare providers actively engaged in advancing our understanding of axSpA and developing innovative treatment solutions. North America has become a hub for clinical trials related to axSpA, fostering collaboration between research institutions, pharmaceutical companies, and healthcare professionals. The region's clinical research infrastructure and ethical standards make it an attractive location for conducting pivotal trials, leading to accelerated drug development and regulatory approvals.

Key Market Players

UCB S.A.

Pfizer Inc.

Abbott laboratories Inc.

Johnson & Johnson

Merck & Co., Inc.

AbbVie Inc.

Novartis AG

Eli Lilly and Company

Amgen Inc.

GlaxoSmithKline plc

NorthStar Rx LLC

Report Scope:

In this report, the Global Axial Spondyloarthritis (axSpA) Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Axial Spondyloarthritis (axSpA) Market, By Type:

Ankylosing spondylitis (AS) Non- radiographic axial spondyloarthritis (nr-axSpA)

Axial Spondyloarthritis (axSpA) Market, By Drug Class:

Non-steroidal anti-inflammatory drugs (NSAID) Glucocorticoids Anti-rheumatic drugs Others

Axial Spondyloarthritis (axSpA) Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Axial Spondyloarthritis (axSpA) Market.

Available Customizations:

Global Axial Spondyloarthritis (axSpA) market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Axial Spondyloarthritis (axSpA) Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Type (Ankylosing spondylitis (AS) and Non- radiographic axial spondyloarthritis (nr-axSpA))
  • 4.2.2. By Drug Class (Non-steroidal anti-inflammatory drugs (NSAID), Glucocorticoids, Anti-rheumatic drugs, Others)
  • 4.2.3. By Region
  • 4.2.4. By Company (2023)
• 4.3. Market Map
  • 4.3.1. By Type
  • 4.3.2. By Drug Class
  • 4.3.3. By Region

5. Asia Pacific Axial Spondyloarthritis (axSpA) Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type
  • 5.2.2. By Drug Class
  • 5.2.3. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Axial Spondyloarthritis (axSpA) Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Type
      • 5.3.1.2.2. By Drug Class
  • 5.3.2. India Axial Spondyloarthritis (axSpA) Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Type
      • 5.3.2.2.2. By Drug Class
  • 5.3.3. Australia Axial Spondyloarthritis (axSpA) Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Type
      • 5.3.3.2.2. By Drug Class
  • 5.3.4. Japan Axial Spondyloarthritis (axSpA) Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Type
      • 5.3.4.2.2. By Drug Class
  • 5.3.5. South Korea Axial Spondyloarthritis (axSpA) Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Type
      • 5.3.5.2.2. By Drug Class

6. Europe Axial Spondyloarthritis (axSpA) Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Drug Class
  • 6.2.3. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Axial Spondyloarthritis (axSpA) Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Drug Class
  • 6.3.2. Germany Axial Spondyloarthritis (axSpA) Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Drug Class
  • 6.3.3. Spain Axial Spondyloarthritis (axSpA) Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Drug Class
  • 6.3.4. Italy Axial Spondyloarthritis (axSpA) Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Type
      • 6.3.4.2.2. By Drug Class
  • 6.3.5. United Kingdom Axial Spondyloarthritis (axSpA) Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Type
      • 6.3.5.2.2. By Drug Class

7. North America Axial Spondyloarthritis (axSpA) Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Drug Class
  • 7.2.3. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Axial Spondyloarthritis (axSpA) Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Drug Class
  • 7.3.2. Mexico Axial Spondyloarthritis (axSpA) Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Drug Class
  • 7.3.3. Canada Axial Spondyloarthritis (axSpA) Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Drug Class

8. South America Axial Spondyloarthritis (axSpA) Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Drug Class
  • 8.2.3. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Axial Spondyloarthritis (axSpA) Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Drug Class
  • 8.3.2. Argentina Axial Spondyloarthritis (axSpA) Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Drug Class
  • 8.3.3. Colombia Axial Spondyloarthritis (axSpA) Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Drug Class

9. Middle East and Africa Axial Spondyloarthritis (axSpA) Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Drug Class
  • 9.2.3. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Axial Spondyloarthritis (axSpA) Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Drug Class
  • 9.3.2. Saudi Arabia Axial Spondyloarthritis (axSpA) Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Drug Class
  • 9.3.3. UAE Axial Spondyloarthritis (axSpA) Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Drug Class

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Axial Spondyloarthritis (axSpA) Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. UCB S.A.
  • 14.1.1. Company Snapshot
  • 14.1.2. Product & Services
  • 14.1.4. Financials (In case of listed)
  • 14.1.5. Recent Developments
  • 14.1.6. SWOT Analysis
• 14.2. Pfizer Inc.
• 14.3. Abbott laboratories Inc.
• 14.4. Johnson & Johnson
• 14.5. Merck & Co., Inc.
• 14.6. AbbVie Inc.
• 14.7. Novartis AG
• 14.8. Eli Lilly and Company
• 14.9. Amgen Inc.
• 14.10. GlaxoSmithKline plc
• 14.11. NorthStar Rx LLC

15. Strategic Recommendations

16. About Us & Disclaimer